

1 **Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and**
2 **could prevent future surges in some populations: a modeling study**

3 Billy J. Gardner, A. Marm Kilpatrick*

4

5 *Department of Ecology and Evolutionary Biology, University of California, Santa Cruz,*
6 *California, USA*

7 **akilpatr@ucsc.edu*

8

9 Summary

10 **Background** Vaccines have greatly reduced the impact of COVID-19 globally. Unfortunately,
11 evidence indicates that immunity wanes following vaccination, especially with the Delta variant
12 (B.1.617.2). Protection against severe disease and death remain high, but protection against
13 milder disease and infection have dropped significantly. A third “booster” dose of two-dose
14 vaccines has been approved in several countries to individuals at higher risk of severe disease to
15 protect those individuals, but the benefit to boosting immunity in younger healthy individuals
16 and the effects on transmission are less clear.

17 **Methods** Here we use relationships between neutralizing antibody titers and vaccine protection
18 against infection and transmission, combined with data on waning and boosting of neutralizing
19 antibody titers to examine the impact of a third dose of the Pfizer vaccine on infection and
20 transmission and its impact on the pathogen effective reproductive number R_t .

21 **Findings** Eight months of waning reduced protection of the Pfizer vaccine against all infections
22 from 80.0% (95% CI: 77% to 83%) to 60.4% (95% CI: 53% to 67%); a third dose (which
23 increased neutralizing antibody titers 25.9- fold relative to levels after 8 months of waning)
24 increased protection to 87.2% (95% CI: 83% to 91%). Increased protection against infection and
25 transmission from third doses reduced R_t by 21% to 66% depending on vaccine coverage and
26 previous infection and reduced R_t below 1 when vaccination coverage was high or contact rates
27 were well below pre-pandemic levels.

28 **Interpretation** A third dose of the Pfizer vaccine could reduce transmission of SARS-CoV-2,
29 which would reduce infection in unvaccinated individuals and breakthrough infections in
30 vaccinated individuals. While vaccination of unvaccinated individuals, especially in developing
31 countries, would be more effective for reducing disease than providing a third dose to vaccinated
32 individuals, the benefit of a third dose in reducing transmission is sizeable and increases with
33 vaccine coverage and contact rates among individuals.

34 **Funding** California Department of Health, National Science Foundation

35

36

37 **Introduction**

38 The emergence of the Delta variant (B.1.617.2) of SARS-CoV-2 has caused a surge of infections
39 globally, even in populations with high vaccination coverage [1, 2]. This is due, in part, to the
40 much higher infectiousness of this virus variant [2, 3], moderate immune evasion [4-6], and,
41 increasingly, waning vaccine immunity, based on both levels of neutralizing antibodies [7-10]
42 and studies of vaccine effectiveness [11-13]. Several countries have recently offered third doses
43 to individuals at higher risk of severe disease [14] because protection for these individuals, even
44 against severe disease, has waned the most [11]. However, protection against severe disease for
45 healthy individuals has waned far less and the need and benefit of providing third doses for young
46 healthy individuals has been questioned [15]. Many populations, especially those in Africa, have
47 received very few vaccine doses and many have argued that vaccinating these populations would
48 provide a larger public health benefit than providing third doses to already vaccinated individuals
49 [15] and for reducing the evolutionary potential of the virus [16].

50 While the direct benefit of providing third doses to elderly and other at-risk individuals is now
51 clear [17], the indirect benefit for reducing transmission of SARS-CoV-2 is poorly understood.
52 Most studies examining waning of vaccine effectiveness over time have focused on protection
53 against symptomatic disease [11-13]. The impact of waning immunity and boosting on vaccine
54 protection against all infections (symptomatic and asymptomatic) and against virus transmission
55 has been mentioned [15], but not quantified, despite its potential importance for reducing
56 infection in unvaccinated individuals and breakthrough infections in vaccinated individuals.

57 Here we extend a previous approach that showed strong correlations between a measure of
58 immunity, neutralizing antibody titers and vaccine protection [18]. This study examined
59 protection against symptomatic disease against non-Delta variants using data from randomized
60 control trials [18]. We extend this approach by mapping neutralizing antibody titers to protection
61 against both symptomatic disease and all infections for both Delta and non-Delta variants. We
62 then use measurements of waning neutralizing antibody titers and boosting with a third dose to
63 estimate the impact on protection against all infections, and the reproductive number of the virus,
64 R_t which quantifies the average number of cases that each case goes on to infect.

65

66 **Methods**

67 *Protection against infection, disease, and transmission*

68

69 We collected data from the literature (including ongoing systematic reviews: [19, 20]) on
70 protective efficacy and effectiveness of vaccines and convalescent sera for SARS-CoV-2 and
71 categorized each study by variant type (Delta and non-Delta; estimates of protection against the
72 Beta variant were excluded) and endpoint (symptomatic infections and all infections) (Table
73 S1). We excluded studies of protection where the endpoint was “any infection” because these
74 studies do not capture all infections; they include an unknown fraction of the asymptomatic
75 infections. We also obtained an estimate of vaccine effectiveness against transmission (given
76 infection) for AstraZeneca (ChAdOx1) and Pfizer-BioNTech (BNT162b2) for the Delta variant
77 [21]. This study quantified secondary attack rates using qPCR tests of contacts that were

78 symptomatic or tested positive using lateral flow tests [21], but likely missed some asymptomatic
79 or mildly symptomatic infected contacts, and thus provides a crude estimate of protection. We
80 gathered neutralizing antibody titer data for each vaccine and ratios of titers to convalescent sera
81 from [18]. Finally, we estimated the ratio of neutralizing antibody titers to the Delta variant
82 relative to earlier variants (Table S2), and used these to adjust neutralizing antibody titer ratio
83 estimates in analyses with vaccine effectiveness or protection from previous infection against the
84 Delta variant (Table S1).

85

86 *Estimating neutralizing antibody titers after waning and third doses*

87

88 We obtained data on neutralizing antibody titers following vaccination for the Pfizer-BioNTech
89 vaccine at several time points between 1 month after the second dose and 8 months post second
90 dose, as well as 1 month after a third dose [10, 22]. One of these studies [22] reported data for
91 two age groups separately (18-55 and 65+), so we weighted these estimates by the fraction of
92 individuals in the age groups 18-60 and 60+ in the United States (71.0% and 29.0%), which is
93 similar to the age distribution in the European Union [23]. We fit these data to a 3-parameter
94 exponentially decaying function ($y = c_0 e^{c_1 * t} + c_2$) to estimate the neutralizing antibody titer on any
95 day, t , post vaccination (Figure 2; Table S4). We also fit similar relationships to data on
96 neutralizing antibody titers over time for the Moderna vaccine [9], and following infection with
97 SARS-CoV-2 [7] (starting when titers peak at 25 days post symptom onset [24]) (Figure 2; Table
98 S4). Rates of waning for hybrid immunity following infection and vaccination with Pfizer-
99 BioNtech and Moderna vaccines combined were statistically similar to rates of waning following
100 vaccination with Pfizer-BioNtech [8], so we used the same relative rates of waning as for Pfizer-
101 BioNtech (Figure 2; Table S4) but adjusted titers for the 7.9-fold higher initial level in those with
102 hybrid immunity [8]. We assumed that boosting individuals that had been infected and then
103 vaccinated resulted in similar neutralizing antibody titers as people that had been vaccinated but
104 not previously infected, because after 6 months of waning post-vaccination, these individuals
105 with hybrid immunity had neutralizing antibody titers that had fallen below levels for newly
106 vaccinated individuals [8].

107

108 *Linking protection against infection and disease with neutralizing antibody titers*

109

110 We modeled the relationship between protection from SARS-CoV-2 infections or disease and the
111 ratio of neutralizing antibody titers relative to convalescent sera using logistic regression,
112 following a previous approach [18]. In this analysis each data point is a single study of protection
113 against SARS-CoV-2 infection or disease for a single virus variant. We included an interaction
114 between neutralizing antibody titers and variant-endpoint to estimate separate relationships for
115 each of four variant-endpoints (pairwise combinations of Delta and non-Delta, symptomatic
116 disease, and all infections). We used the separate relationship for the Delta – all infections
117 endpoint for all analyses described below.

118

119 The raw data for each estimate of protection (vaccine efficacy, vaccine effectiveness, or
120 protection from previous infection) were unavailable, so we determined the effective sample
121 sizes for a sample from a binomial distribution that matched the confidence intervals of the
122 protection estimates (Table S1). We used the fitted model (Figure 1) to estimate protection
123 against all infections for the Delta variant from Pfizer - BioNTech vaccination using neutralizing

124 antibody titers measured after eight months of waning and titers measured after a 3rd dose [22].
125 We performed a similar analysis using the limited data available to link neutralizing antibody
126 titers to protection against transmission given infection [21] (Figure S1).

127

128 *The impact of a third dose on the reproductive number, R_t*

129

130 We used patterns of waning and boosting of neutralizing antibody titers and the relationships
131 between neutralizing antibody titers and protection against all infections and transmission to
132 estimate the impact of providing a third dose of the Pfizer – BioNTech vaccine to increasing
133 fractions of vaccinated individuals on the reproductive number of SARS-CoV-2, R_t . The
134 effective reproductive number, R_t , is the average number of secondary cases that each case
135 infects. It is equal to the basic reproductive number for a fully susceptible population, R_0 ,
136 multiplied by the fraction of the population that is still susceptible. We split the population based
137 on vaccination and infection to determine the effective fraction susceptible: fraction previously
138 infected and unvaccinated, f_{PU} , fraction previously infected and vaccinated, f_{PV} ; fraction
139 unvaccinated, f_U , fraction vaccinated (with two doses of either Pfizer-BioNTech or Moderna), f_V ,
140 and fraction boosted with a third dose, f_B ($f_U+f_V+f_B=1$). We estimated the susceptibility of each
141 group using estimates of the protection against infection, VE_I , (Figure 1) and the reduced
142 probability of transmitting given infection, VE_T , (Figure S1) for each group using the subscripts
143 above, except VE_{IH} and VE_{TH} which are estimates of protection from hybrid immunity from
144 infection and vaccination. We used these estimates of protection to calculate R_t for five groups of
145 people : fully susceptible unvaccinated $(1-f_P)f_U$, previously infected unvaccinated f_Pf_U ,
146 previously uninfected vaccinated $(1-f_P)f_V$, previously infected vaccinated f_Pf_V , and previously
147 uninfected vaccinated and boosted with a third dose $(1-f_P)f_B$:

148

$$149 R_t = R_0 [(1-f_{PU})f_U + f_{PU}f_U(1-VE_{IP})(1-VE_{TP}) + (1-f_{PV})f_V(1-VE_{IV})(1-VE_{TV}) + (f_{PV}f_V)(1-VE_{IH})(1-VE_{TH}) + (f_B)(1-VE_{IB})(1-VE_{TB})]$$

150

151 We examined the effect of boosting vaccinated individuals with a third dose by considering five
152 scenarios that differ in contact rates/ R_0 ($R_0 = 3.7$ or 7 reflecting mid-summer 2021 levels in the
153 USA and pre-pandemic behavior, respectively), vaccination coverage (56% similar to USA in
154 mid-October [23]; 60%, 75% and 100%), and the fraction of the population previously infected
155 (0.5%, 28.2% and 56.4%, with the last value being similar to estimates of the fraction of the
156 USA population that had been infected by mid-October, based on 44 million cases and an
157 infection to case ratio of 4.2 [25]). The scenarios and rationale were (Table S5):

158

- 159 1) $R_0 = 3.7$, 56% vaccinated, 56.4% previously infected: approximates USA population in
160 mid-October with contact rates similar to summer 2021, as might occur in winter 2021
- 161 2) $R_0 = 3.7$, 60% vaccinated, 0.5% previously infected: approximates countries/populations
162 that effectively suppressed transmission and haven't yet reached high vaccination levels
163 and have somewhat reduced contact rates (e.g. New Zealand, Australia, Hong Kong, etc.)
- 164 3) $R_0 = 3.7$, 75% vaccinated, 28.2% previously infected: approximates some populations
165 with higher vaccination and lower fraction infected than scenario (1) (e.g. California)
- 166 4) $R_0 = 7$, 100% vaccinated, 56.4% previously infected: a hypothetical optimistic scenario
167 to compare to scenario (1) to determine if vaccination with or without boosting could
168 limit transmission if behavior returns to pre-pandemic levels
- 169

170 5) $R_0 = 7$, 56% vaccinated, 56.4% previously infected: a more realistic optimistic scenario
171 to compare to scenario (1) to determine if boosting could limit transmission if behavior
172 returns to pre-pandemic levels
173


174 For all scenarios we estimated the waning of vaccine-derived immunity as of October 15, 2021
175 using the timing of vaccination in the USA [26]; Figure S2) and patterns of waning neutralizing
176 antibody titers over time for Pfizer-BioNtech and Moderna vaccines or hybrid immunity (Figure
177 2). We estimated the waning of infection-derived immunity as of October 15, 2021 using the
178 timing of deaths in the USA [23] shifted by 24 days [27] (Figure S3) and the rate of waning of
179 infection-derived immunity (Figure 2). We estimated the number of infections in vaccinated and
180 unvaccinated people using the ratios of cases in these two groups over time [28] (Figure S4). We
181 used these data on the timing of vaccination and infection and rates of antibody waning to
182 determine the protection against infection and transmission as of October 15, 2021 (Table S6).
183 We calculated 95% CIs for predicted values of R_t that incorporated uncertainty in the
184 relationships between neutralizing antibody titers and protection against infection and
185 transmission (Figures 1 and S4). We drew 10,000 samples from a uniform distribution $c(0,1)$ and
186 used these as quantiles for a normal distribution to generate draws (on a logit scale) for values of
187 protection VE for each value of neutralizing antibody titer adjusted for waning for the fraction of
188 the population that was vaccinated or infected at each day in the past. This approach essentially
189 drew a single line from the 95% CI of lines in Figure 1 and used that for all levels of waning. We
190 then inverse-logit transformed these values of VE and used them to generate 10,000 values of R_t
191 for that scenario. We took the 2.5% and 97.5% quantiles to estimate the 95% confidence
192 intervals (CIs) for R_t for each point of each scenario.
193

194 Results

195 There were strong relationships between the ratio of neutralizing antibody titers to convalescent
196 sera and protection against both symptomatic infection and all infections (Figure 1; Table S3).
197 Protection was highest for symptomatic disease for non-Delta variants and lower for protection
198 against all infections for both non-Delta and Delta variants (Figure 1; Table S3).

199 Neutralizing antibodies generated by vaccination with the Pfizer-BioNtech vaccine wane 8.06-
200 fold after 8 months (Figure 1), with most of this waning occurring in the first 3 months (Figure
201 2). The strong relationship between protection and neutralizing antibody titers (Figure 1; Table
202 S3) suggests that this waning of neutralizing antibody titers will reduce protection against all
203 infections for the Delta variant from 80.0% (95% CI: 77.0% to 83.0%) to 60.4% (95% CI: 53.3%
204 to 67.2%) (Figure 1, red line, compare points labelled “Pfizer 1 week” to “Pfizer 8 mo waning”;
205 Figure 2 purple point). Similarly, this waning reduced the protection against transmission given
206 infection from 38% (95% CI: 28% to 47%) to 10.5% (95% CI: 6.6% to 16.4%) (Figure S4). A
207 third dose of the Pfizer-BioNtech vaccine boosted antibody titers 25.9-fold relative to levels after
208 8 months of waning, or $25.9/8.06 = 3.22$ higher than one week after dose 2 [22]. The fitted
209 relationship (Figure 1; Table S3) suggests a third dose of the Pfizer-BioNtech vaccine would
210 increase protection against infection from an eight-month waned value of 60.4% (95% CI: 53.3%
211 to 67.2%) to a boosted value of 87.2% (95% CI: 82.8% to 90.7%) and would boost protection
212 against transmission given infection from 10.5% to 60.7% (95% CI: 42.3% to 76.5%) (Figure
213 S1).

214




215

216 **Fig. 1. Protection against symptomatic infections or all infections plotted against the ratio**
217 **of neutralizing antibody titers relative to convalescent sera. Each point represents a single**
218 **estimate of vaccine efficacy for a single vaccine & virus variant (from randomized control**
219 **trials) or vaccine effectiveness (from observational studies) or an estimate of protection**
220 **from previous infection from observational studies. Colors show the SARS-CoV-2 variant**
221 **(Delta or non-Delta) and endpoint of the study (symptomatic infections or all infections).**
222 **Closed symbols and 95% CIs show aggregated data for each vaccine-variant-endpoint.**
223 **Open symbols show estimates from individual studies if there were more than one estimate**
224 **for a vaccine-variant-endpoint. Points have been jittered along the x-axis to facilitate**
225 **presentation; all points for the same vaccine-variant have the same x-value. Lines show a**
226 **fitted logistic regression with protection as the response and an interaction between and**
227 **neutralizing antibody ratio and variant-endpoint as predictors (Table S3). The lower panel**
228 **shows relationships for the Delta variant, with all points shifted 2.88-fold lower along the x-**
229 **axis to reflect the lower neutralizing antibodies observed with this variant across studies**
230 **(Table S2).**

231 Neutralizing antibody titers waned for both vaccine-derived immunity (Pfizer-BioNtech
232 and Moderna vaccines) and infection derived immunity (Figure 2A, B). Rates of waning were
233 fastest for the Pfizer-BioNtech vaccine, followed by infection-generated antibodies, whereas
234 antibodies from the Moderna vaccine waned the slowest (Figure 2B; Table S4). Antibodies from
235 infection stabilized at a slightly higher level relative to their peak than either vaccine (Figure
236 2B), but starting antibodies were lowest for infection, followed by Pfizer-BioNtech and then
237 Moderna (Figure 2A).

238 We used the relationship between neutralizing antibody titers and protection against
239 infection for the Delta variant (Figure 1; Table S3), and patterns of waning of antibody titers

240 (Figure 2A, B) to estimate the waning of protection against all infections over time (Figure 2C).
241 Earlier work suggested that antibodies from infection followed by vaccination (“hybrid
242 immunity”) were 7.9-fold higher than for Pfizer-BioNtech vaccination and waned at a similar
243 rate as Pfizer-BioNtech [8], so we used the same Pfizer-BioNtech neutralizing antibody decay
244 curve, but adjusted for the much higher initial peak. Protection against all infections was highest
245 for Hybrid immunity, followed by Moderna, Pfizer and then infection-derived immunity. The
246 relatively fast and sustained waning rate of neutralizing antibodies for the Pfizer-BioNtech
247 vaccine suggests that protection from this vaccine was initially higher than infection-derived
248 immunity but the two were similar after four months (Figure 2C).




249
250 **Figure 2. Waning of neutralizing antibodies and protection against infection over time. A)**
251 **Neutralizing antibody titers relative to convalescent sera, adjusted for lower neutralization**
252 **titers with the Delta variant. B) The same data as in panel (A) but rescaled to be relative to**
253 **the peak initial value so rates of waning and levels of stabilization can be visualized and**
254 **analyzed simultaneously (Table S4). C) Protection against infection over time using the**
255 **patters of waning in Figure 2A and the relationships between antibody titers and**
256 **protection against infection (Figure 1 red line).**

257

258 Boosting immunity, by providing a third dose of the Pfizer-BioNtech to all doubly vaccinated
259 individuals in the USA (56% of the total population), could reduce the reproductive number R_t
260 by 22% from 1.26 to 0.98 and stop a surge (Figure 3, red line), assuming current levels of
261 vaccination coverage (56%), estimated immunity from previous infection (56.4%), and behavior
262 consistent with the summer Delta surge ($R_0=3.7$) (see Methods for further details).
263 Unfortunately, in places where vaccination is slightly higher (60%), but previous infection is
264 much lower, (0.5%; e.g. New Zealand), boosting with a third dose would be unable to prevent a
265 surge with the same contact rates (Figure 3, grey line). Conversely, in populations where
266 vaccination is higher (75%) and previously infection is lower (28.2%) (e.g. California), boosting
267 at least 45% of the population (60% of those vaccinated) could push R_t below 1 (Figure 3 blue
268 line).

269 If contact rates return to pre-pandemic levels ($R_0=7$), with mid-October USA vaccine coverage
270 (56%) and infection history (56.4%), then boosting could reduce R_t by a larger absolute amount
271 (but the same relative amount, 21%) than with lower contact rates, from 2.37 to 1.85 (Figure 3,
272 green line) but cases would still rise rapidly because 1.85 is still far above 1. Using the same
273 number of 3rd doses to doubly vaccinate unvaccinated individuals would be more impactful, and
274 could reduce R_t to 1.49 (Figure 3, compare right end of green line to black point labelled 84%
275 vaccinated on left side). If contact rates return to pre-pandemic levels ($R_0=7$), then even if a
276 population had 100% vaccination coverage and 56.4% previously infected, waning of vaccine
277 and infection-derived immunity would cause cases to continue to grow without boosting (Figure
278 3, left end of yellow line: $R_t=1.17$ which is greater than 1; without waning R_t would be 0.74, well
279 below 1). However, boosting >21% of a fully (100%) vaccinated population could prevent a
280 surge in cases, even with pre-pandemic behavior (Figure 3, yellow line).



281

282 **Figure 3. Relationship between third dose coverage and the pathogen effective reproductive**
283 **number, R_t . Lines and 95% CIs show the estimated reproductive number for five scenarios**
284 **(see Methods). The single black point shows the impact of using all third doses from the**
285 **right end of the green line to doubly-vaccinate unvaccinated individuals, which would**
286 **bring the vaccination coverage from 56% to 84%. Protection from vaccination and**
287 **previous infection for all lines reflect waning, as described in the text (Table S3). The**
288 **dashed horizontal line shows the threshold reproductive number $R_t = 1$, separating a**
289 **growing from a shrinking epidemic.**

290

291 Discussion

292 Vaccines have greatly reduced the impact of COVID-19 globally, but waning immunity and the
293 emergence of the Delta variant have led to surges in cases despite high vaccination coverage in
294 many populations [1, 7-10]. This has led to many countries recommending third doses to boost
295 immunity to protect at-risk individuals [14]. However, the impact of third doses on transmission
296 of SARS-CoV-2 has received far less attention [15].

297 We found that a third dose could substantially reduce transmission, especially in highly
298 vaccinated populations, and the effect was larger in populations with lower acquired immunity
299 from infection and when contact rates (which scale R_0) were higher. We showed that neutralizing
300 antibodies are strongly correlated not just with protection against symptomatic disease [4, 18],
301 but also with protection against all infection and transmission given infection (Figures 1, S4).
302 This allowed us to estimate the effect of waning and boosting on transmission, and the pathogen
303 reproductive number R_t . Boosting immunity by providing a third dose to individuals vaccinated
304 more than three months ago (after most waning has occurred: Figure 2) could reduce
305 transmission substantially and could prevent a winter surge in many populations where
306 vaccination coverage is high, as long as contact rates and behavior don't fully return to pre-
307 pandemic levels. In contrast, with pre-pandemic contact rates, only very high levels of vaccine
308 coverage, and a combination of a moderate level of previous infection and boosting could
309 prevent a surge.

310 We also found that despite the substantial potential impact of boosting on transmission,
311 deploying vaccine doses to unvaccinated individuals has a larger effect on transmission (Figure
312 3, compare the black point to the right end of the green line). In addition, the direct effect of
313 vaccinating unvaccinated people is much larger than the benefit of providing a third dose for
314 severe disease and death since protection against severe disease has only waned slightly, except
315 in older or at-risk individuals [11]. Unfortunately, vaccine hesitancy among those not vaccinated
316 is quite high in many populations (e.g., USA, Russia, etc.) and many people are unwilling to get
317 vaccinated despite strong incentives, often due to misinformation [29-31], making it difficult to
318 increase vaccine coverage in some populations. In contrast, there other populations where
319 vaccine coverage is very low, primarily due to poor availability, especially in Africa [32].
320 Clearly, limited vaccine doses would be most effectively used in these populations and should be
321 deployed there until supplies are no longer limiting.

322 Our study has several limitations. First and foremost is the reliance on neutralizing antibody
323 titers as a predictor of protection against infection and transmission. Although the analyses here,
324 and elsewhere suggest a strong relationship between neutralizing antibody titers and protection at
325 the population level [4, 18] and individual level [33], other parts of the immune system, such as
326 T-cells, also play key roles in protection, especially against severe disease. Second, our analyses
327 use population averages for estimates of protection against infection and transmission and ignore
328 age-specific variation among individuals (as well as other factors). Third, the data available to
329 estimate vaccine protection against all infections and against transmission given infection from
330 the Delta variant was limited. Fourth, it's unclear how long antibody titers will be elevated
331 following a third dose, so the effect of boosting might not be long lasting. Finally, we assume
332 well-mixed populations in calculating reductions in the reproductive number R_t . Clearly a
333 targeted vaccination approach would be more effective than that outlined here if individuals that
334 were highly connected to at-risk individuals could be targeted for third doses [34]. Finally, we
335 focused on third dose boosters using the Pfizer vaccine, but third doses for other vaccines,
336 including heterologous boosting [35], have also recently been approved in the USA and
337 elsewhere.

338 In summary, many countries have already begun to deploy third doses to protect at-risk
339 individuals, and some countries (e.g. Israel, [17]) have even deployed third doses to the general
340 population to reduce transmission. However, uptake in most countries has been low, criteria for
341 third doses are still vague [14], and only moderate effort has been deployed to deploy third doses
342 widely. Our results suggest that widespread boosting of the general population could
343 substantially reduce transmission. Polls in some countries suggest a large fraction of the
344 vaccinated population would be willing to get a third dose (e.g., 76% of Americans; [36]). If
345 vaccine doses for providing initial doses to populations with very low coverage are not limiting,
346 then offering third doses to the general public could play a significant role in reducing
347 transmission. This would directly protect boosted individuals [37], indirectly protect
348 unvaccinated and vaccinated individuals, and reduce the possibilities for viral evolution [16].

349

350 **Contributors**

351 AMK conceived the study. BJG and AMK performed the analyses and wrote the paper.

352 **Declaration of interests**

353 All authors declare no competing interests.

354 **Data sharing**

355 Code and data files to replicate the figures and analyses of this paper can be found at:

356 <https://github.com/marmkilpatrick/Vaccine-boosters>

357 **Acknowledgements**

358 We thank the Kilpatrick lab for helpful comments.

359 **References**

- 360 1. Wadman M. Israel's grim warning: Delta can overwhelm shots. *Science*.
361 2021;373(6557):838-9.
- 362 2. Elliott P, Haw D, Wang H, Eales O, Walters CE, Ainslie KEC, et al. Exponential growth,
363 high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant.
364 *Science*. 0(0):eab19551. doi: doi:10.1126/science.abl9551.
- 365 3. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al.
366 Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.
367 *Eurosurv*. 2021;26(24):2100509.
- 368 4. van Gils MJ, Lavell AHA, van der Straten K, Appelman B, Bontjer I, Poniman M, et al.
369 Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-
370 CoV-2 variants. *medRxiv*. 2021:2021.09.27.21264163. doi: 10.1101/2021.09.27.21264163.
- 371 5. Davis C, Logan N, Tyson G, Orton R, Harvey W, Haughney J, et al. Reduced
372 neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.
373 *medRxiv*. 2021:2021.06.23.21259327. doi: 10.1101/2021.06.23.21259327.
- 374 6. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al.
375 Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*.
376 2021;596(7871):276-80.
- 377 7. Havervall S, Marking U, Gordon M, Ng H, Greilert-Norin N, Lindbo S, et al.
378 Neutralization of VOCs including Delta one year post COVID-19 or vaccine. *medRxiv*.
379 2021:2021.08.12.21261951. doi: 10.1101/2021.08.12.21261951.
- 380 8. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al.
381 mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.
382 *Science*. 2021:eabm0829.
- 383 9. Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, et al.
384 Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-
385 19. *N Engl J Med*. 2021;384(23):2259-61.
- 386 10. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune
387 humoral response to BNT162b2 covid-19 vaccine over 6 months. *New England Journal of*
388 *Medicine*. 2021.
- 389 11. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Vaccine
390 effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and
391 severe COVID-19 in the UK. *medRxiv*. 2021.
- 392 12. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Haas E, et al.
393 Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel. *medRxiv*. 2021.
- 394 13. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al.
395 Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. *N Engl J*
396 *Med*. 2021.
- 397 14. Furlong A, Deutsch J. A country-by-country guide to coronavirus vaccine booster plans
398 2021. Available from: [https://www.politico.eu/article/vaccine-booster-coronavirus-covid-19-](https://www.politico.eu/article/vaccine-booster-coronavirus-covid-19-europe-delta-varian-who/)
399 [europe-delta-varian-who/](https://www.politico.eu/article/vaccine-booster-coronavirus-covid-19-europe-delta-varian-who/).
- 400 15. Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, et al.
401 Considerations in boosting COVID-19 vaccine immune responses. *Lancet (London, England)*.
402 2021;398(10308):1377-80. doi: 10.1016/S0140-6736(21)02046-8. PubMed PMID: 34534516.
- 403 16. Wagner CE, Saad-Roy CM, Morris SE, Baker RE, Mina MJ, Farrar J, et al. Vaccine
404 nationalism and the dynamics and control of SARS-CoV-2. *medRxiv*. 2021.

- 405 17. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al.
406 Protection of BNT162b2 vaccine booster against covid-19 in Israel. *N Engl J Med*.
407 2021;385(15):1393-400.
- 408 18. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
409 Neutralizing antibody levels are highly predictive of immune protection from symptomatic
410 SARS-CoV-2 infection. *Nat Med*. 2021:1-7.
- 411 19. Higdon MM, Wahl B, Jones CB, Rosen JG, Truelove SA, Baidya A, et al. A systematic
412 review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and
413 disease. *medRxiv*. 2021:2021.09.17.21263549. doi: 10.1101/2021.09.17.21263549.
- 414 20. WHO. Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic
415 Review 2021. Available from: [https://view-hub.org/sites/default/files/2021-
416 09/COVID19%20VE%20Studies_Forest%20Plots_1.pdf](https://view-hub.org/sites/default/files/2021-09/COVID19%20VE%20Studies_Forest%20Plots_1.pdf).
- 417 21. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. The impact of
418 SARS-CoV-2 vaccination on Alpha and Delta variant transmission. *medRxiv*.
419 2021:2021.09.28.21264260. doi: 10.1101/2021.09.28.21264260.
- 420 22. Falsey AR, Frenck Jr RW, Walsh EE, Kitchin N, Absalon J, Gurtman A, et al. SARS-
421 CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. *N Engl J Med*. 2021.
- 422 23. CDC. COVID Data Tracker 2021. Available from: [https://covid.cdc.gov/covid-data-
423 tracker/#vaccinations_vacc-total-admin-rate-total](https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total).
- 424 24. Arkhipova-Jenkins I, Helfand M, Armstrong C, Gean E, Anderson J, Paynter RA, et al.
425 Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living
426 review. *Ann Intern Med*. 2021;174(6):811-21. doi: doi.org/10.7326/M20-7547.
- 427 25. CDC. Estimated COVID-19 Burden 2021. Available from:
428 <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html>.
- 429 26. CDC. COVID-19 Vaccinations in the United States 2021. Available from:
430 https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total.
- 431 27. Lewnard JA, Liu VX, Jackson ML, Schmidt MA, Jewell BL, Flores JP, et al. Incidence,
432 clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California
433 and Washington: prospective cohort study. *BMJ-British Medical Journal*. 2020;369:10. doi:
434 10.1136/bmj.m1923. PubMed PMID: WOS:000538336800001.
- 435 28. CDC. Rates of COVID-19 Cases and Deaths by Vaccination Status 2021. Available
436 from: <https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status>.
- 437 29. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigran A, et al. Vaccine
438 hesitancy: the next challenge in the fight against COVID-19. *Eur J Epidemiol*. 2020;35(8):775-9.
- 439 30. Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of
440 vaccine acceptance rates. *Vaccines*. 2021;9(2):160.
- 441 31. Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. *Nat Med*.
442 2021;27(8):1338-9.
- 443 32. Acharya KP, Ghimire TR, Subramanya SH. Access to and equitable distribution of
444 COVID-19 vaccine in low-income countries. *npj Vaccines*. 2021;6(1):1-3.
- 445 33. Gilbert PB, Montefiori DC, McDermott A, Fong Y, Benkeser D, Deng W, et al. Immune
446 Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. *medRxiv*.
447 2021:2021.08.09.21261290. doi: 10.1101/2021.08.09.21261290.
- 448 34. Firth JA, Hellewell J, Klepac P, Kissler S, Kucharski AJ, Spurgin LG. Using a real-world
449 network to model localized COVID-19 control strategies. *Nat Med*. 2020;26(10):1616-22.

- 450 35. Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al.
451 Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report. medRxiv.
452 2021:2021.10.10.21264827. doi: 10.1101/2021.10.10.21264827.
- 453 36. Aboulenein A, Kahn C. Most vaccinated Americans want COVID-19 booster shots -
454 Reuters/Ipsos poll: Reuters; 2021. Available from: [https://www.reuters.com/business/healthcare-
455 pharmaceuticals/most-vaccinated-americans-want-covid-19-booster-shots-reutersipsos-poll-
456 2021-09-01/](https://www.reuters.com/business/healthcare-pharmaceuticals/most-vaccinated-americans-want-covid-19-booster-shots-reutersipsos-poll-2021-09-01/).
- 457 37. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of
458 a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in
459 Israel: an observational study. *The Lancet*. 2021.
- 460 38. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness
461 of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection
462 and severe covid-19 outcomes in Ontario, Canada: test negative design study. *BMJ*.
463 2021;374:n1943. doi: 10.1136/bmj.n1943.
- 464 39. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA
465 Covid-19 vaccine in a nationwide mass vaccination setting. *N Engl J Med*. 2021;384(15):1412-
466 23.
- 467 40. Emary KR, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of
468 ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.
469 1.1. 7): an exploratory analysis of a randomised controlled trial. *The Lancet*.
470 2021;397(10282):1351-62.
- 471 41. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine
472 coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine
473 against infection (SIREN): a prospective, multicentre, cohort study. *The Lancet*.
474 2021;397(10286):1725-35.
- 475 42. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.
476 Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. *N Engl J Med*.
477 2021:585-94.
- 478 43. Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et
479 al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and
480 hospitalisation, Navarre, Spain, January to April 2021. *Eurosurv*. 2021;26(21):2100438.
- 481 44. Narrainen F, Shakeshaft M, Asad H, Holborow A, Blyth I, Healy B. The protective effect
482 of previous COVID-19 infection in a high-prevalence hospital setting. *Clinical Medicine*.
483 2021;21(5):e470.
- 484 45. Nasreen S, He S, Chung H, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of
485 COVID-19 vaccines against variants of concern, Canada. *Medrxiv*. 2021.
- 486 46. Pouwels KB, Pritchard E, Matthews P, Stoesser NB, Eyre DW, Vihta K-D, et al. Impact
487 of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the
488 UK. *medRxiv*. 2021.
- 489 47. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D, et al. Impact of
490 vaccination on new SARS-CoV-2 infections in the United Kingdom. *Nat Med*. 2021:1-9.
- 491 48. Satwik R, Satwik A, Katoch S, Saluja S. ChAdOx1 nCoV-19 effectiveness during an
492 unprecedented surge in SARS COV-2 infections. *European Journal of Internal Medicine*. 2021.
- 493 49. Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane F, Al Khatib HA, et al.
494 BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B. 1.617. 2)
495 variant in Qatar. *MedRxiv*. 2021.

- 496 50. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-
 497 dose administration and the influence of the timing of the booster dose on immunogenicity and
 498 efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
 499 The Lancet. 2021;397(10277):881-91.
- 500 51. Whitaker H, Tsang R, Byford R, Andrews N, Sherlock J, Pillai P. Pfizer-BioNTech and
 501 Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals
 502 in clinical risk groups. Khub net Posted July. 2021.
- 503 52. Richardson JR, Goetz R, Mayr V, Lohse MJ, Holthoff H-P, Ungerer M. SARS-COV2
 504 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after
 505 infection. medRxiv. 2021.
- 506 53. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody
 507 activity against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination. The
 508 Lancet. 2021;397(10292):2331-3.
- 509 54. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Ability of AZD1222
 510 vaccination to elicit neutralising antibodies against SARS-CoV-2 VOC B. 1.617. 2 (Delta).
 511 Lancet (London, England). 2021;398(10296):207.

512

513

514 Supplemental Tables and Figures

515 **Table S1. Data and studies used to estimate the relationship between protection (VE)**
 516 **against infection, disease and transmission endpoints and neutralizing antibody titer (NAT)**
 517 **ratios relative to convalescent sera (Figure 1). A single value of the neutralizing antibody**
 518 **titer ratio was used for each vaccine and variant; values for the Delta variant are 2.88-fold**
 519 **lower than for non-Delta variants (Table S2). N_{eff} are the effective sample sizes used for the**
 520 **logistic regression (Table S3).**

Study	Vaccine or Convalescent	Variant	Endpoint	NAT Ratio	VE (95% CI)	N_{eff}
[13]	Moderna	non-Delta	Symptomatic	4.13	0.99 (0.92-1.00)	70
[38]	Moderna	non-Delta	Symptomatic	4.13	0.94 (0.86-0.97)	112
[38]	Pfizer	non-Delta	Symptomatic	2.37	0.91 (0.88-0.93)	550
[39]	Pfizer	non-Delta	Symptomatic	2.37	0.94 (0.87-0.98)	96
[40]	Astrazeneca	non-Delta	Symptomatic	0.54	0.75 (0.42-0.89)	16
[21]	Astrazeneca	Delta	Transmission	0.19	0.16 (0.12-0.21)	243
[21]	Pfizer	Delta	Transmission	0.82	0.38 (0.28-0.47)	109
[41]	Convalescent	non-Delta	All infections	1	0.83 (0.76-0.87)	168
[41]	Pfizer	non-Delta	All infections	2.37	0.86 (0.76-0.97)	49
[18]	Astrazeneca	non-Delta	Symptomatic	0.54	0.62 (0.41-0.76)	34
[18]	Convalescent	non-Delta	Symptomatic	1	0.89 (0.66-0.98)	18
[18]	CoronaVac	non-Delta	Symptomatic	0.17	0.50 (0.36-0.62)	60
[18]	JJ	non-Delta	Symptomatic	0.47	0.67 (0.59-0.74)	147
[18]	Moderna	non-Delta	Symptomatic	4.13	0.94 (0.89-0.97)	150
[18]	Novavac	non-Delta	Symptomatic	3.97	0.96 (0.68-0.99)	25

[18]	Pfizer	non-Delta	Symptomatic	2.37	0.95 (0.90-0.98)	200
[18]	Sputnik	non-Delta	Symptomatic	1.41	0.92 (0.85-0.95)	140
[42]	Astrazeneca	Delta	Symptomatic	0.19	0.67 (0.61-0.72)	330
[42]	Astrazeneca	non-Delta	Symptomatic	0.54	0.75 (0.68-0.79)	240
[42]	Pfizer	Delta	Symptomatic	0.82	0.88 (0.85-0.90)	750
[42]	Pfizer	non-Delta	Symptomatic	2.37	0.94 (0.92-0.95)	720
[43]	Pfizer	non-Delta	Symptomatic	2.37	0.82 (0.73-0.88)	110
[44]	Convalescent	non-Delta	All infections	1	0.97 (0.81-1.00)	25
[45]	Astrazeneca	non-Delta	Symptomatic	0.54	0.91 (0.62-0.98)	22
[45]	Astrazeneca	Delta	Symptomatic	0.19	0.87 (0.69-0.95)	32
[45]	Moderna	non-Delta	Symptomatic	4.13	0.92 (0.88-0.95)	225
[45]	Moderna	non-Delta	Symptomatic	4.13	0.96 (0.85-0.99)	50
[45]	Moderna	Delta	Symptomatic	1.44	0.95 (0.91-0.97)	220
[45]	Pfizer	non-Delta	Symptomatic	2.37	0.89 (0.86-0.91)	1440
[45]	Pfizer	Delta	Symptomatic	0.82	0.92 (0.90-0.94)	600
[45]	Pfizer	non-Delta	Symptomatic	2.37	0.93 (0.88-0.95)	210
[46]	Astrazeneca	Delta	All infections	0.19	0.67 (0.62-0.71)	420
[46]	Astrazeneca	non-Delta	All infections	0.54	0.79 (0.56-0.90)	25
[46]	Convalescent	Delta	All infections	0.35	0.72 (0.58-0.82)	53
[46]	Convalescent	non-Delta	All infections	1	0.60 (0.50-0.68)	125
[46]	Pfizer	Delta	All infections	0.82	0.80 (0.77-0.83)	780
[46]	Pfizer	non-Delta	All infections	2.37	0.78 (0.68-0.84)	100
[47]	Astrazeneca	non-Delta	All infections	0.54	0.79 (0.65-0.88)	50
[47]	Pfizer	non-Delta	All infections	2.37	0.80 (0.73-0.85)	185
[48]	Convalescent	Delta	Symptomatic	0.35	0.93 (0.87-0.96)	169
[49]	Moderna	Delta	Symptomatic	1.44	0.86 (0.71-0.94)	42
[49]	Pfizer	Delta	Symptomatic	0.82	0.56 (0.41-0.67)	64
[50]	Astrazeneca	non-Delta	All infections	0.54	0.56 (0.41-0.67)	63
[51]	Astrazeneca	non-Delta	Symptomatic	0.54	0.78 (0.70-0.84)	150
[51]	Pfizer	non-Delta	Symptomatic	2.37	0.93 (0.86-0.97)	100

521

522 **Table S2. Ratios of neutralizing antibody titers to Delta or non-Delta variants of SARS-**
 523 **CoV-2 from vaccination or infection SARS-CoV-2.**

Reference	non-Delta variant	Sample type	Ratio non-Delta to Delta
[4]	D614G	Pfizer-BioNtech	4.5
[4]	D614G	Astrazeneca	4.5
[22]	Wild Type	Pfizer-BioNtech	1.28
[5]	Wuhan	Pfizer-BioNtech	11.30
[5]	Wuhan	Astrazeneca	4.01
[52]	Wild Type	Pfizer-BioNtech	2.1
[52]	Wild Type	Astrazeneca	2.1
[53]	Wild Type	Pfizer-BioNtech	5.8

[54]	Wild Type	Astrazeneca	8.0
[7]	Wild Type	Pfizer-BioNtech	1.18
[7]	Wild Type	Astrazeneca	1.22
[6]	D614G	Pfizer-BioNtech	2.0
[6]	D614G	Astrazeneca	5.0
[4]	D614G	Convalescent	2.1
[6]	D614G	Convalescent	2.1
		Estimated ratio*	2.88

524 *There was no significant difference in the ratios among sample types (either vaccines or
 525 convalescent sera): mixed effects model of log-transformed ratio with Sample Type as a fixed
 526 effect and study as a random effect; likelihood ratio $\chi^2(df=2) = 2.6$; $P = 0.26$.

527

528 **Table S3. Logistic regression analysis of protection (vaccine efficacy or effectiveness or**
 529 **protection from previous infection) with the log-transformed ratio of neutralizing antibody**
 530 **titers (NAT-Ratio) relative to convalescent sera, with an interaction with four groups for**
 531 **variant (Delta and non-Delta) and endpoint (symptomatic cases or all infections) as shown**
 532 **in Figure 1. Delta – infection was the reference level.**

Predictor	Estimate	SE	Z-value	P-value
Intercept	1.47	0.10	14.49	<0.0001
log ₂ (NAT-Ratio)	0.32	0.064	4.97	<0.0001
non-Delta – symptomatic	0.10	0.11	0.87	0.39
non-Delta – infection	-0.41	0.13	-3.00	0.0027
Delta – symptomatic	0.77	0.13	5.79	<0.0001
log ₂ (NAT-Ratio):non-Delta - symptomatic	0.27	0.076	3.59	0.00034
log ₂ (NAT-Ratio):non-Delta - infection	-0.035	0.12	-0.29	0.77
log ₂ (NAT-Ratio):Delta - symptomatic	0.22	0.089	2.50	0.012

533

534 **Table S4. Analysis of waning rates of neutralizing antibodies for two vaccines (Pfizer-**
 535 **BioNtech and Moderna) and infection-derived immunity. The best fitting model by AIC**
 536 **was Antibody titer = (c₀+c₇*Infection)*e^(c₁*Day+c₃*Day*Moderna+c₄*Infection*Day)+c₂+c₆*Infection,**
 537 **where Pfizer-BioNtech was the reference level. There was no support for Moderna having a**
 538 **different asymptote than Pfizer (P-values>0.45 for coefficients similar to c₇ and c₆).**

Coefficient	Estimate	SE	t-value	P-value
c ₀	0.90	0.032	28.42	<0.0001
c ₁	-0.023	0.0024	-9.77	<0.0001
c ₂	0.12	0.026	4.49	0.0012
c ₃	0.013	0.0021	5.96	0.0001
c ₄	0.0092	0.0044	2.11	0.061
c ₆	0.18	0.044	4.13	0.0020
c ₇	-0.20	0.061	-3.21	0.0094

539

540 **Table S5. Fraction of the population in each group for the five scenarios in Figure 3, using**
 541 **the case ratios in vaccinated and unvaccinated individuals and the timing of vaccinations**
 542 **and infections derived from COVID-19 deaths and vaccinations as of October 15, 2021 in**
 543 **the USA (Figures S2-S4).**

Scenario	Fraction vaccinated and infected ($f_{PV} * f_V$)	Fraction vaccinated and not infected ($(1-f_{PV}) * f_V$)	Fraction unvaccinated and infected ($f_{PU} * f_U$)	Fraction fully susceptible ($((1-f_{PU}) * f_U)$)
R0=3.7; 56% vacc., 56.4% prev. inf.	0.26	0.30	0.30	0.14
R0=3.7; 60% vacc., 0.52% prev. inf.	0.0012	0.60	0.004	0.40
R0=3.7; 75% vacc., 28.2% prev. inf.	0.18	0.57	0.11	0.14
R0=7; 100% vacc., 56.4% prev. inf.	0.56	0.44	0	0
R0=7; 56% vacc., 56.4% prev. inf.	0.26	0.30	0.30	0.14

544

545


546 **Table S6. Estimated protection (and 95% CI) against infection (VE_I) and transmission**
 547 **(VE_T) given waning of vaccine and infection derived immunity, as of October 15, 2021 in**
 548 **the USA, using case ratios in vaccinated and unvaccinated individuals and the timing of**
 549 **vaccinations and infections derived from COVID-19 deaths and vaccinations (Figures S2-**
 550 **S4). These estimates are derived from the rates of waning of neutralizing antibody titers**
 551 **(Figure 2; Table S4) and the relationship between neutralizing antibody titers and**
 552 **protection against infection for Delta (Figure 1; Table S3) and transmission given infection**
 553 **(Figure S1).**

Endpoint	Estimate with waning (95% CI)
VE_{IP} (infected and unvaccinated)	0.627 (0.565-0.685)
VE_{TP} (infected and unvaccinated)	0.125 (0.086-0.181)
VE_{IV} (vaccinated and uninfected)	0.675 (0.637-0.712)
VE_{TV} (vaccinated and uninfected)	0.186 (0.152-0.226)
VE_{IH} (vaccinated and infected)	0.827 (0.792-0.857)
VE_{TH} (vaccinated and infected)	0.464 (0.341-0.583)
VE_{IB} (boosted with third dose)	0.873 (0.828-0.907)

VE_{TB} (boosted with third dose)	0.608 (0.428-0.764)
-------------------------------------	---------------------

554

555




556

557 **Figure S1. Protection against transmission given infection plotted against the ratio of**
558 **neutralizing antibody titers relative to convalescent sera from infection with SARS-CoV-2**
559 **for Astrazeneca (left filled triangle) and Pfizer (right filled triangle) [21]. The raw data is in**
560 **Table S1 – Transmission endpoint. Open squares show the estimated protection with**
561 **waning (left open square) and boosting (right open square). The fitted model is:**
562 **$\text{logit}(\text{Protection}) = -0.336 (\pm 0.225) + 0.549 (\pm 0.124) * \text{log}_2(\text{neut. antibody ratio}); P < 0.0001.$**

563


564



565

566 **Figure S2. Number of people fully vaccinated in the USA [26].**


567



568

569 **Figure S3. COVID-19 cases, deaths, and infections inferred from deaths in the USA [23].**

570



571

572 **Figure S4. Ratio of COVID-19 cases in unvaccinated individuals relative to vaccinated**
573 **individuals in the USA in 2021 [28].**

574